Category: 169447-70-5

169447-70-5, (S)-tert-Butyl 2-methylpiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 1 ,1 -dimethylethyl (2S)-2-methyl-1-piperazinecarboxylate(100 mg, 0.5 mmol) in CH2CI2 (5 ml_) was mixed with 3-bromo benzaldehyde (0.06 ml_, 0.5 mmol) and NaB(OAc)3H (0.16 g, 0.75 mmol). The resulting mixture was stirred for 12 hours, diluted with dichloromethane (30 ml_) and washed with brine (50 ml_). The organic layer was collected, dried over Na2SO4 and concentrated. Separation via a combiflash system then afforded the title compound (150 mg, 81%): LC/MS: m/z, 369 (M+H); 1HNMR (MeOD) delta 1.26 (3H, d), 1.47 (9H, s), 2.0 (1 H, m), 2.1 (1 H, m), 2.6 (1 H, m), 2.8 (1 H, m), 3.1 (1 H, m), 3.3 (2H, s), 3.4 (1 H, m), 3.5 (1 H, m), 3.8 (1 H, m), 4.2 (1 H, m), 4.88 (1 H, s), 7.25 (1 H, m), 7.3 (1 H, m), 7.4 (1 H, m), 7.55 (1 H, s).

169447-70-5, The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2006/55553; (2006); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

Example 69; Preparation of Compound 69B; Step A; A solution of 4-chloro-3-nitro-pyridine (2.0 mmol, 0.32 g), diethylisopropyl amine (3.0 mmol, 0.52 mL) and 2(s)-methyl-piperazine-1-carboxylic acid tert-butyl ester (2.5 mmol, 0.50 g) in dioxane (2 mL) was irradiated using microwave for 20 minutes at a temperature of 120 C. The reaction mixture was concentrated in vacuo, and the resulting residue was purified using flash column chromatography on silica gel (eluent: ethyl acetate) to provide compound 69A as a yellow solid in quantitative yield. HPLC-MS RT= 1.42 min, mass calculated for formula C15H22N4O4 322.16, observed LCMS m/z 323.1 (M+H)., 169447-70-5

The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SCHERING CORPORATION; WO2008/54749; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

Example 69; Preparation of Compound 69B; Step A; A solution of 4-chloro-3-nitro-pyridine (2.0 mmol, 0.32 g), diethylisopropyl amine (3.0 mmol, 0.52 mL) and 2(s)-methyl-piperazine-1-carboxylic acid tert-butyl ester (2.5 mmol, 0.50 g) in dioxane (2 mL) was irradiated using microwave for 20 minutes at a temperature of 120 C. The reaction mixture was concentrated in vacuo, and the resulting residue was purified using flash column chromatography on silica gel (eluent: ethyl acetate) to provide compound 69A as a yellow solid in quantitative yield. HPLC-MS RT= 1.42 min, mass calculated for formula C15H22N4O4 322.16, observed LCMS m/z 323.1 (M+H)., 169447-70-5

The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SCHERING CORPORATION; WO2008/54749; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

169447-70-5, (S)-tert-Butyl 2-methylpiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 1 ,1-dimethylethyl (2S)-2-methyl-1-piperazinecarboxylate (1.5g, 7.5 mmol) in anhydrous DCM (3OmL) was added triethylamine (2.59ml_, 19 mmol) and 2,4-difluoro-1-isocyanatobenzene (0.88ml_, 7.5 mmol) the sample was stirred under an argon atmosphere at room temperature for 2hours. The reaction was evaporated and the residue was suspended DCM (3OmL) which was washed with 0.5M aqueous HCI (10OmL), and then water (10OmL). The collected organic layer was dried (MgSO4), filtered and evaporated, the residue was dried in a vac-oven at 400C overnight (approx 18hours) to yield the title compound as a white solid (2.41 g, 91%).1H NMR (CDCI3) 51.22 (3H, d, J=6.58Hz), 1.48 (9H, s), 3.11 (1 H, m), 3.22 (1 H, m), 3.34 (1 H, dd, J=13.37, 3.95Hz), 3.71 (1 H, m), 3.92 (1 H, m), 4.31 (1 H, br m), 6.39 (1 H, NH, br m), 6.85 (2H, m), 7.99 (1 H, m)., 169447-70-5

The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXO GROUP LIMITED; BESWICK, Paul, John; CAMPBELL, Alister; CRIDLAND, Andrew; GLEAVE, Robert, James; PAGE, Lee, William; WO2010/102663; (2010); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

169447-70-5, (S)-tert-Butyl 2-methylpiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a dried flask was added (S)-tert-butyl 2-methylpiperazine-1-carboxylate (52.3 mg, 0.261 mmol),rac-benzyl ((2S,3R,4R)- I -acetyl-6-bromo-2-cyclopropyl-3-methyl- 1,2 ,3,4-tetrahydroquinolin-4-yl)carbamate (for a preparation see Intermediate 13, 99.5 mg, 0.218 mmol), sodium tert-butoxide (41.8 mg, 0.435 mmol), Pd2(dba)3 (9.96 mg, 10.88 pmol) and DavePhos (8.56 mg, 0.022 mmol) under nitrogen. To this was added 1,4-dioxane (2 mL), and the solution was stirred and degassed with nitrogen for -15 mm. The mixture was heated to 90 C overnight. The mixture was allowed tocool to rt, filtered through a 2.5 g celite cartridge, washed through with ethyl acetate and concentrated in vacuo. The residue was taken up in dichloromethane, loaded onto a 25 g silica flash column, and eluted in 10%-50% ethyl acetate in cyclohexane. The appropriate fractions were collected and concentrated in vacuo to afford a yellow oil (48.4 mg, 0.084 mmol, 38.6%). This was a mixture of diastereoisomers. LCMS (2 mm formic): Rt = 1 .29 mi [MH] = 577., 169447-70-5

The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; AMANS, Dominique; ATKINSON, Stephen John; HARRISON, Lee Andrew; HIRST, David Jonathan; LAW, Robert Peter; LINDON, Matthew; PRESTON, Alexander; SEAL, Jonathan Thomas; WELLAWAY, Christopher Roland; WO2014/140076; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

Methanesulphonyl chloride (467mu, 5.99 mmol) was added to a stirred solution of (S)-ferf-butyl 2- methylpiperazine-1-carboxylate (1 .0 g, 4.99 mmol) in dichloromethane (20 mL) and pyridine (2 mL). The reaction mixture was stirred at room temperature overnight. The solvent was evaporated. The residue was dissolved in diethyl ether (50 mL) and washed with 1 M hydrochloric acid (25 mL) followed by water (25 mL) and brine (25 mL). The organic phase was dried and evaporated. The product was dissolved in diethyl ether (20 mL) and treated with 4M hydrogen chloride in 1 ,4-dioxane (4 mL) and allowed to stand at room temperature overnight. The solvent was evaporated. The residue was triturated with diethyl ether, was filtered off, washed with diethyl ether and dried to give (S)-3-methyl-1-(methylsulphonyl)piperazine hydrochloride (457 mg, 2.128 mmol, 42.6% yield) as a colourless solid. 1H NMR (400MHz, CDCI3) delta-ppm 3.78-3.60 (m, 2H); 3.08 (dt, J = 12 Hz and J = 4 Hz, 1 H); 2.95 (J = 12 Hz and J = 4 Hz, 1 H); 2.95-2.86 (m, 2H); 2.77 (s, 3H); 2.70 (td, J = 8 Hz and J = 4Hz, 1 H); 2.31 (dd, J = 12 Hz and J = 12 Hz, 1 H); 1.09 (d, J = 8 Hz, 3H)., 169447-70-5

The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXOSMITHKLINE LLC; AMANS, Dominique; BAMBOROUGH, Paul; BIT, Rino, Antonio; BROWN, John, Alexander; CAMPBELL, Matthew; LINDON, Matthew, John; SHIPLEY, Tracy, Jane; THEODOULOU, Natalie, Hope; WELLAWAY, Christopher, Roland; WESTAWAY, Susan, Marie; WO2014/78257; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

169447-70-5, (S)-tert-Butyl 2-methylpiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 1-34 (10 g, 50 mmol), 1 , 4-dibromobenzene (29.4 g, 125 mmol), cesium carbonate (24.3 g, 75 mmol) and BINAP (1.5 g, 2.5 mmol) in 1,4-dioxane (250 mL) was degassed in a stream of argon for 15 minutes. To the mixture was added tris (dibenzylideneacetone) dipalladium(O) (0.900 g, 2.5 mmol), and the reaction mixture was again degassed for additional 15 minutes. After stirring at 90C for 18 hours, the. volatiles were removed by evaporation, and the obtained residue was diluted with water (250 mL) , followed by extraction with ethyl acetate (250 mL x 3) . The combined organic layers were washed with brine (50 mL) , dried over anhydrous Na2S04 and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (60-120 mesh) using 10% EtOAc in hexanes to give the desired product 1-35 as a white solid (5.5 g, 31%); LCMS : m/z 357.1 [M+l] , 359.1, 169447-70-5

As the paragraph descriping shows that 169447-70-5 is playing an increasingly important role.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; KOUL, Summon; KURHADE, Suresh; BHOSALE, Sandeep; NAIK, Keshav; SALUNKHE, Videsh; MUNOT, Yogesh; BHUNIYA, Debnath; (284 pag.)WO2015/88045; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

Step 1: (S)-tert-butyl 4-(3,4-difluorophenyl)-2-methylpiperazine-1-carboxylate A mixture of 4-bromo-1,2-difluorobenzene (1 g, 5.18 mmol), (S)-tert-butyl 2-methylpiperazine-1-carboxylate (1.04 g, 5.18 mmol), t-BuONa (747 mg, 7.77 mmol), BINAP (40 mg, 0.06 mmol) and Pd2(dba)3 (20 mg, 0.02 mmol) in toluene (15 mL) was stirred at 80 C. for 3 hrs. The mixture was then purified by chromatography (silica, EtOAc/PE=1/8) to afford (S)-tert-butyl-4-(3,4-difluorophenyl)-2-methylpiperazine-1-carboxylate (921 mg, 2.95 mmol, 57%) as product. ESI-MS (EI+, m/z): 257.1 [M-55]+.

169447-70-5, As the paragraph descriping shows that 169447-70-5 is playing an increasingly important role.

Reference£º
Patent; Navitor Pharmaceuticals, Inc.; O’Neill, David John; Saiah, Eddine; Kang, Seong Woo Anthony; Brearley, Andrew; Bentley, Jonathan; (136 pag.)US2019/389843; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

169447-70-5, To a stirred solution of tert-butyl (2S)-2-methylpiperazine-1-carboxylate(1 g, 4.99 mmol, 1 equiv.) and DIEA(1.3 g, 9.99 mmol, 2 equiv.) in DMA(10 mL) was added 4,5-dibromo-2,3- dihydropyridazin-3-one (1.5 g, 5.91 mmol, 1.183 equiv.) in portions at 100 degrees C overnight. The reaction liquid was purified by reverse phase flash with the following conditions: (0292) MeCN/H2O (NH4CO3: 5%) (MeCN: 50%-95%,40 min) to afford tert-butyl (2S)-4-(5-bromo-6- oxo-1,6-dihydropyridazin-4-yl)-2-methylpiperazine-1-carboxylate(1.2g,64.39%) as a yellow solid.

The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GOLDFINCH BIO, INC.; YU, Maolin; DANIELS, Matthew, H.; HARMANGE, Jean-christophe, P.; TIBBITTS, Thomas, T.; LEDEBOER, Mark, W.; WALSH, Liron; MUNDEL, Peter, H.; MALOJCIC, Goran; (860 pag.)WO2019/55966; (2019); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

A 100 mL round-bottom flask was charged with 2-chloro-4-(morpholin-4- yl)benzaldehyde (0.800 g, 3.54 mmol, 1.00 equiv), tert-butyl (2S)-2-methylpiperazine-l- carboxylate (0.783 g, 3.91 mmol, 1.10 equiv) , 1,2-dichloroethane (20 mL). The mixture was stirred for 30 min at room temperature. Sodium triacetoxyborohydride (2.26 g, 10.7 mmol, 3.00 equiv) was added. The resulting solution was stirred overnight at room temperature, diluted with ]0 (30 mL), extracted with dichloromethane (3 x 30 mL) and the organic layers were combined, dried over Na2S04, filtered and concentrated under reduced pressure. The residue was chromatographed on a silia gel column with ethyl acetate/petroleum ether (25/75) to provide 1.20 g (74% yield) of tert-butyl (2S)-4-[[2-chloro-4-(morpholin-4- yl)phenyl]methyl]-2-methylpiperazine-l-carboxylate as a white solid. LCMS (ESI, m/z): 410 [M+H]+., 169447-70-5

Big data shows that 169447-70-5 is playing an increasingly important role.

Reference£º
Patent; ABIDE THERAPEUTICS; THE SCRIPPS RESEARCH INSTITUTE; CISAR, Justin, S.; GRICE, Chery, A.; JONES, Todd, K.; NIPHAKIS, Micah, J.; CHANG, Jae, Won; LUM, Kenneth, M.; CRAVATT, Benjamin, F.; WO2013/103973; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics